Asset Details
Do you wish to reserve the book?
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Do you wish to request the book?
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
2013
Overview
Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC.
Publisher
Future Medicine Ltd
Subject
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Humans
/ Lung Neoplasms - drug therapy
/ molecular targeted therapies
/ Mutation
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Receptor, Epidermal Growth Factor - antagonists & inhibitors
